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STUDY PROTOCOL Open Access
Trial protocol OPPTIMUM– Does progesterone
prophylaxis for the prevention of preterm labour
improve outcome?
Jane E Norman1*, Andrew Shennan2, Phillip Bennett3, Steven Thornton4, Stephen Robson5, Neil Marlow6,
John Norrie7, Stavros Petrou8, Neil Sebire9, Tina Lavender10 and Sonia Whyte11
Abstract
Background: Preterm birth is a global problem, with a prevalence of 8 to 12% depending on location.. Several
large trials and systematic reviews have shown progestogens to be effective in preventing or delaying preterm
birth in selected high risk women with a singleton pregnancy (including those with a short cervix or previous
preterm birth). Although an improvement in short term neonatal outcomes has been shown in some trials these
have not consistently been confirmed in meta-analyses. Additionally data on longer term outcomes is limited to a
single trial where no difference in outcomes was demonstrated at four years of age of the child, despite those in
the “progesterone” group having a lower incidence of preterm birth.
Methods/Design: The OPPTIMUM study is a double blind randomized placebo controlled trial to determine
whether progesterone prophylaxis to prevent preterm birth has long term neonatal or infant benefit. Specifically it
will study whether, in women with singleton pregnancy and at high risk of preterm labour, prophylactic vaginal
natural progesterone, 200 mg daily from 22 – 34 weeks gestation, compared to placebo, improves obstetric
outcome by lengthening pregnancy thus reducing the incidence of preterm delivery (before 34 weeks), improves
neonatal outcome by reducing a composite of death and major morbidity, and leads to improved childhood
cognitive and neurosensory outcomes at two years of age. Recruitment began in 2009 and is scheduled to close in
Spring 2013. As of May 2012, over 800 women had been randomized in 60 sites.
Discussion: OPPTIMUM will provide further evidence on the effectiveness of vaginal progesterone for prevention of
preterm birth and improvement of neonatal outcomes in selected groups of women with singleton pregnancy at
high risk of preterm birth. Additionally it will determine whether any reduction in the incidence of preterm birth is
accompanied by improved childhood outcome.
Trial registration: ISRCTN14568373
Background, including rationale and any previous
systematic review(s)
Preterm birth is a global problem, with a prevalence of 8
to 12% depending on location [1]. Around 75% of pre-
term birth follows spontaneous preterm labour, some-
times preceded by preterm premature membrane
rupture [2]. Babies born preterm are at increased risk of
a variety of adverse short term (neonatal) and long term
complications, including neurodevelopmental disability.
Women with a previous preterm birth (especially those
women who delivered before 34 weeks following spon-
taneous preterm labour), women with a short cervix in
early pregnancy [3], and women with a previous cone bi-
opsy or laser loop excision to the cervix [4] are at all at
increased risk of spontaneous preterm birth.
Several large trials and meta-analyses have shown pro-
gesterone to be effective in preventing or delaying pre-
term birth in selected high risk women (short cervix or
previous preterm birth) with singleton pregnancy [5-11].
There is data that both intramuscular 17 hydroxyproges-
terone caproate and vaginal progesterone are effective in
preventing preterm birth. OPPTIMUM likewise is
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investigating the efficacy of progesterone in women at
elevated risk of preterm birth, but will crucially address
longer term childhood developmental outcomes.
Although an improvement in short term neonatal out-
comes has been shown in some trials [6-8] these have
not consistently been confirmed in meta-analyses [9,10].
Data on longer term outcomes in singletons is limited to
follow up of babies of women in the Meis trial, where
80% of babies were assessed by questionnaire at a mean
age of four years. No differences in childhood outcomes
were demonstrated, despite the progesterone group hav-
ing a lower incidence of preterm birth [12].
The mechanisms of action of progesterone are some-
what uncertain although a direct inhibitory effect on the
processes of parturition seem likely [13]. Additionally
progesterone could exert anti-inflammatory properties
[13] and/or direct CNS protective effects [14], which
could help to reduce the risk or severity of long term
neonatal problems.
If the prevention of preterm birth is accompanied by a
reduction in the complications of prematurity, then in
utero progesterone should be predicted to have long term
beneficial effects. Harmful long term effects are however
also possible. Although direct teratogenic effects of pro-
gesterone are unlikely, there could be adverse effects of
keeping the fetus in utero in a compromised intrauterine
environment where infection or inflammation is present.
Caution is therefore warranted before progesterone use
becomes widespread, particularly since drugs (including
antibiotics and estrogens) thought to be beneficial in
women at risk of preterm birth have now been demon-
strated to have long term adverse effects [15-17].
The OPPTIMUM study is designed to determine
whether progesterone prophylaxis to prevent preterm
birth has long term neonatal or childhood benefit. Specif-
ically it will study whether, in women at elevated risk of
preterm labour, prophylactic vaginal natural progester-
one, 200 mg (compared to placebo), daily from 22 –
24 weeks up to 34 weeks gestation, improves obstetric
outcome by lengthening pregnancy thus reducing the in-
cidence of preterm delivery (before 34 weeks), improves
neonatal outcome by reducing a composite of death and
major morbidity and leads to improved childhood cogni-
tive and neurosensory outcomes at two years of age.
The OPPTIMUM study began recruiting in January
2009. Since then, one large, and several other smaller
studies have reported the effect of progesterone, either as
vaginal progesterone or as intramuscular 17 hydroxypro-
gesteronecaproate. None fully addresses the crucial
question regarding long term outcome (childhood devel-
opment at 2 years). Additionally, we note that the US
Food and Drug Administration (FDA) has indicated
that long term childhood outcome data are required to
determine the clinical benefits and risks of 17
hydroxyprogesteronecaproate for the prevention of pre-
term birth in women with a previous preterm birth..
a An
FDA panel also recently ruled that data supplied on vagi-
nal progesterone gel “do not [yet] support the efficacy of
progesterone gel compared with placebo in reducing the
risk of preterm births before 33 completed weeks of ges-
tation among women with a short cervical length”.b We
believe that OPPTIMUM will address these important
evidence gaps about the efficacy of vaginal progesterone
and any childhood effects of progestogens in general.
Methods
Aim(s)
The aim of the OPPTIMUM study is to determine
whether, in women at high risk of preterm labour,
prophylactic vaginal natural progesterone, 200 mg daily
from 22 – 34 weeks gestation, compared to placebo:
 Improves obstetric outcome by reducing the
incidence of preterm delivery (before 34 weeks
gestation).
 Improves neonatal outcome by reducing a
composite of death and major morbidity.
 Leads to improved childhood cognitive and
neurosensory outcomes at two years.
Centre(s)
More than 60 hospitals, principally in the UK.
Design
Double blind randomized placebo controlled trial. The
study is in two phases, a screening phase and a treat-
ment phase.
Inclusion and exclusion criteria
Screening phase inclusion criteria
High risk for preterm birth (as indicated by AT LEAST
ONE of the criteria i-iv) and ALL of the criteria v-vii:
i. History of previous PTB/second trimester loss
(≥16 weeks or ≤37 weeks gestation)
ii. Previous preterm premature rupture of the fetal
membranes (≤ 37 weeks gestation)
iii. Short cervical length (≤ 25 mm) on ultrasound at
18–0 -24 + 0 weeks gestation
iv. Any cervical procedure to treat abnormal smears i.e.
large loop excision, laser conisation, cold knife
conisation or radical diathermy
v. Gestation established by scan at ≤ 16 weeks to
ensure that the estimated date of delivery is accurate
or the consultant must be confident that the
gestation dates are accurate.
vi. Signed Consent form
vii.16 years of age or older.
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Treatment phase inclusion criteria
 All women fulfilling the inclusion criteria for the
screening phase and who also have a positive
screening (fFN) test at 22 + 0 weeks, will be eligible
for the main (treatment) phase of the study – these
women are subsequently referred to as the “fFN
positive” group.
 Additionally, in September 2010, those who have a
previous spontaneous labour resulting in a preterm
birth ≤ 34 weeks gestation (delivery by any mode) or
a short cervix in index pregnancy, defined as
cervical length ≤ 25 mm at 18–0 -24 + 0 weeks
gestation also became eligible for randomisation
even with a negative fFN test. These women are
subsequently referred to as the “fFN negative” group
Exclusion criteria
 Known significant congenital structural or
chromosomal fetal anomaly
 Known sensitivity or listed contraindication to
progesterone (known allergy or hypersensitivity to
progesterone, severe hepatic dysfunction,
undiagnosed vaginal bleeding, mammary or genital
tract carcinoma, thrombophlebitis, thromboembolic
disorders, cerebral haemorrhage, porphyria) or
intolerance to progesterone or excipient (including
peanut allergy prior to February 2011 given that
peanut oil was the excipient in doses issued to
participants until November 2010)
 Suspected or proven rupture of the fetal membranes
at the time of recruitment
 Multiple pregnancy
 Prescription or ingestion of medications known to
interact with progesterone (e.g. Bromocriptine,
Rifamycin, Ketoconazole or Ciclosporin)
 Women currently prescribed progesterone or who
have taken progesterone beyond 18 weeks gestation.
Intervention(s) Progesterone (Utrogestan) 200 mg soft
capsules or placebo will to be inserted once daily vagi-
nally at bedtime from 22+0 - 24+0 up to 34+0 weeks
gestation.
Randomisation
Randomisation will be carried out online via the web
portal or via telephone to the central randomisation fa-
cility based at the Robertson Centre for Biostatistics, at
the Glasgow Clinical Trials Unit, University of Glasgow.
Concealment of allocation
Concealment of allocation will be achieved by randomis-
ing participants to active or placebo capsules. Placebo
capsules will appear identical to active treatment. The
outcomes will be measured blind to the allocation.
Primary and any secondary endpoint(s)
Primary endpoints:
 Obstetric: delivery <34 completed weeks of gestation
(Yes/No), (<34 + 0 weeks: outcome of the treatment
phase)
 Neonatal: a composite of death or two markers of
neonatal morbidity – bronchopulmonary dysplasia
in children born at <32 weeks of gestation and brain
injury on cerebral ultrasound.
 Childhood: The Bayley III cognitive scale
standardised score at two years of chronological age
(with an aim to test between 22 months to
26 months - as this is age-standardised all
assessments will be valid)
Secondary endpoints:
 Gestation at delivery
 Fetal or neonatal/infant death after trial entry up to
2 years of age [18].
 Incidence of the individual components of the
primary neonatal outcome
 Incidence of other major neonatal complications:
 Level of care days, which includes: days of
respiratory support, (Either mechanical ventilation
or CPAP) and days of oxygen therapy.
 Surfactant administration
 Necrotising enterocolitis, (medical or surgical
treatment of confirmed cases)
 Number of discrete episodes of bloodstream or CNS
infection (positive blood [19] or CSF culture)
 Daily level of care [20].
 Composite outcome of death or moderate/severe
neurodevelopmental impairment at two years of age,
defined as per national recommendations [21].
 Individual components of the disability definition
and non-neurological disability as defined [21].
 Strengths and difficulties questionnaire (http://www.
sdqinfo.com/)
 Score on the PARCA-r (parent assessment of child
abilities revised).
 Women’s perceptions of their treatment.
 Maternal and child adverse events (e.g. operative
delivery).
Side-effects reporting and quantification (e.g, WHO scale)
Participants are instructed to contact their Investigator
at any time after consenting to join the trial if any symp-
toms or side effects develop. In the case of any events
the Investigator should initiate the appropriate treatment
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according to their medical judgment. All adverse events
(AEs) and Serious Adverse Events (SAE) that occur after
being randomized to treatment must be recorded in de-
tail in the patient notes. SAEs occurring in mother or
baby from the time a participant is randomised until
30 days after stopping taking study treatment/placebo or
until 28 days after delivery (whichever is the later)
should be reported to the co-sponsors using the trial
documentation. The standard definition of a serious ad-
verse event will be used [22]. This is any event that:
results in death; is life threatening (i.e. the subject was at
risk of death at the time of the event; it does not refer to
an event which hypothetically might have caused death
if it were more severe); requires hospitalisation or pro-
longation of existing hospitalisation; results in persistent
or significant disability or incapacity; is a congenital
anomaly or birth defect. Hospitalisations for treatment
planned prior to randomisation and hospitalisation
for elective treatment of a pre-existing condition will
not be considered as an SAE, nor, for the purposes of
this study, will the following events: miscarriage, preterm
labour / suspected preterm labour, premature rupture
of membranes (PROM) / suspected PROM, preterm
delivery, preterm delivery in maternal interest, preterm
delivery in fetal interest, hospitalisation for pregnancy
induced hypertension, hospitalisation for “maternal dis-
comfort”, hospitalisation for “rest”, hospitalisation for
“observation” or “monitoring” for which the women
are admitted for a period of less than 12 hours;
normal” childhood illnesses (including infectious dis-
eases and minor injuries) and complications arising from
prematurity.
Statistical analysis plan, including sample size and power
calculations
At the commencement of the study in 2008, we planned
to recruit 750 women in the “fFN positive” group. We esti-
mated that such a sample size would provide 80 – 95%
power at the 5% level of significance for the primary ob-
stetric outcome, 80% power for the neonatal outcome and
93% power for the childhood outcome (although further
dilution of the latter was anticipated after incorporation of
the deaths in a two stage statistical model – see below).
In 2010, the study was expanded to allow randomisa-
tion of women in the “fFN negative” group after analysis
of preliminary (blinded) data in July 2010, together with
the result of an HTA funded systematic review on
screening for preterm birth [23] showed that our initial
selection strategy erroneously missed women at medium
to high risk of preterm birth. This change was endorsed
by the Trial Steering committee, the MHRA, the ethics
committee, and by the funder. The inclusion of women
at a lower risk of the primary outcomes necessitated an
increase in the sample size. The minimum new sample
size is anticipated to be in the order of 1125 (375 fFN
positive and 750 fFN negative women), but the propor-
tions of each will dictate the exact sample size, as it is
anticipated that at least 2 fFN negative women are
required to achieve the event rate predicted in 1 fFN
positive woman. Workings for the sample size calcula-
tion for the fFN positive group alone, and for the revised
combined group of fFN positive and fFN negative
women are shown in the Appendix.
Type of analysis (e.g. intention to treat) and statistical
tests
All primary efficacy analyses are carried out on the
intention to treat population (ITT). Safety analyses are
carried out on the safety population (those who initiated
on what study medication they received). Primary ana-
lyses are repeated in an exploratory manner on the per
protocol population (including [i] compliance within an
acceptable range and [ii] fulfilment of inclusion and ex-
clusion criteria).
Obstetric outcome
The primary obstetric outcome is delivery or fetal death
before 34 completed weeks of gestation based on ultra-
sound (based on the projected date of delivery estimated
from scan in the first trimester). The following null hy-
pothesis will be tested: ‘There is no difference in the inci-
dence of delivery or fetal death before 34 completed weeks
of gestation between the group treated with 200 mg / day
progesterone and the group treated with placebo from
week 22–24 to week 34 of gestation or earlier delivery’.
The outcome is compared between the treatment
groups using a logistic regression model including treat-
ment and previous pregnancy of at least 14 weeks. The
hypothesis will be tested with a likelihood ratio test.
Neonatal outcome
The primary neonatal outcome is a binary outcome indi-
cating whether one of the following has occurred:
 Death
 Brain injury (defined as any intraventricular
haemorrhage (IVH) (excludes subependymal
haemorrhages), parenchymal cystic or haemorrhagic
lesion or persistent ventriculomegaly (VI >97th
percentile)
 Severe chronic lung disease (defined as need for
≥30% oxygen and/or positive pressure (positive
pressure ventilation or nasal continuous positive
airway pressure) at 36 weeks post menstrual age or
discharge, which ever comes first).
The following null hypothesis will be tested: ‘There is
no difference in the combined incidence of neonatal
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death, brain injury or severe chronic lung disease be-
tween the group treated with 200 mg / day progesterone
and the group treated with placebo from week 22–24 to
week 34 or earlier delivery’ This outcome is also com-
pared between the treatment groups using a logistic re-
gression model including treatment and previous
pregnancy of at least 14 weeks. The hypothesis will be
tested with a likelihood ratio test.
Childhood outcome
The primary childhood outcome is the Bayley III score,
a continuous measure. This outcome will, by definition,
not be available on babies who have died. Thus deaths
need to be incorporated into the analysis, since the
number of deaths may be sufficiently large as not to be
negligible, and/or there may be a difference in the num-
ber of deaths between the two randomised groups. We
will therefore use a two-stage statistical model that
jointly models the treatment effect in both deaths and
survivors [24], with deaths modelled using a binomial
test and survivors modelled using a generalised linear
model. The two parts are then combined to form the ap-
propriate test statistic. Secondary analyses that adjust
the estimated treatment effect for covariates felt to be of
importance will be used as appropriate. Note that we
will not be adjusting for gestational age in our analysis
of childhood outcomes. The hypothesised mechanism of
action of progesterone is to increase gestational age by
reducing the proportion of women giving birth prema-
turely. To adjust for a post randomisation covariate (ges-
tational age) which is a direct measure of the treatment
effect, in a model that is estimating the consequence of
that treatment effect (in terms of developmental out-
come) is not statistically sound.
A fully detailed Statistical Analysis Plan will be pre-
pared prior to unblinding.
Planned subgroup analyses
In order to determine whether a reduced or improved
response to progesterone can be predicted, subgroups of
the ITT population will be formed according to the fol-
lowing factors:
 reason for risk of preterm delivery (spontaneous
preterm birth yes / no and any preterm birth
yes / no)
 previous pregnancy of at least 14 weeks (yes / no)
 cervical length at 18–24 weeks gestation
(≤25 mm / >25 mm and ≤15 mm / >15 mm)
 chorioamnionitis diagnosed on pathology (yes / no)
Ethical issues, including: Ethics committee approval
The study has been approved by the Scotland (A) Re-
search Ethics Committee, reference number 08/MRE00/6.
Interim analyses and stopping rules
Interim unblinded analyses will be performed on safety,
efficacy and possibly futility criteria for the purposes of
review by the independent Data Monitoring Committee
(iDMC) only. Masking will be maintained and analysis
of obstetric and neonatal outcomes will be deferred until
conclusion of the two-year childhood assessments. Thus
no interim analyses will be revealed to investigators, par-
ticipants, or anyone other than the DMC members (and
statistical advisors) until completion of the two-year
childhood assessments.
Committee oversights
There is an independent Trial Steering Committee and
independent Data Monitoring Committee.
Indemnities
The sponsor has clinical trial insurance which covers
this study. This insurance includes indemnification for
the TSC and DMC. There is no “no fault” indemnity.
Publication plan
The results of the trial will be published in peer
reviewed journals. The results of the obstetric and neo-
natal outcomes will not be published until data collec-
tion for the childhood follow up part of the study is
complete.
Funding
The study is funded by the MRC/EME -funder reference
G0700452, grant No: 84982
Start date
Recruitment began in January 2009, as of May 2012,
over 800 women had been randomized
End of data collection
Estimated October 2015
Reporting date
Estimated mid 2016
Trial registration
ISRCTN14568373
Discussion
Despite the many publications on the use of progester-
one for the prevention of preterm birth, we believe that
that further data, particularly on the long term effect for
the baby, is needed before the use of progesterone can
be routinely recommended in pregnant women at high
risk of preterm birth. Many authorities, including the
FDAa and the Royal College of Obstetricians in the UKc
agree. The Society of Obstetricians and Gynecologists of
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Canada (SOGC) [25] suggests that women at risk of
should be encouraged to enroll in trials of progesterone,
although the SOGC also gives advice about the dose and
formulation of progestogens for women who have opted
to take them. Other authorities endorse the use of pro-
gesterone based on current literature. For example the
American College of Obstetricians and Gynecologists, in
guidelines published in 2008 and reaffirmed in 2011 [26]
is more positive about the use of progesterone, saying
that “progesterone supplementation for the prevention
of recurrent preterm birth should be offered to women
with a singleton pregnancy and a prior spontaneous pre-
term [before 37 weeks] birth” and that “progesterone
supplementation for asymptomatic women with a very
short cervical length (less than 15 mm) may be consid-
ered”. In 2012, the Society of Maternal and Fetal Medi-
cine Publications committee suggests that women with
singleton pregnancies with prior preterm birth be given
17 alpha hydroxyprogesterone, and that those with a
short cervix ≤ 20 mm be given vaginal progesterone (al-
though they indicate that routine screening is “an object
of debate”) [13].
The OPPTIMUM study will provide further evidence
on the effectiveness of vaginal progesterone for the pre-
vention of preterm delivery in selected high risk women.
Crucially, it will also determine whether prevention of
preterm birth by progesterone prophylaxis is associated
with long term benefit for the baby.
Appendix
Sample size calculations
Original sample size calculation based on data in the
literature on the “fFN +” group
A sample size of 750 (375 per group) gives adequate
statistical power to detect clinically important and plaus-
ible differences in the three primary measures of out-
come. All these power calculations allow for loss to
follow up rates and compliance. Delivery <34 weeks on
placebo is expected to be 40% (data from an untreated
high risk UK population with a positive fFN test at
22 weeks [27] and 27% on progesterone consistent with
the odds ratio of 0.45 for the overall PTB with any pro-
gestational agent in the most recent systematic review
[28]. With 750 randomised, the study will have 95%
power at a 5% level of significance to detect such a re-
duction from 40% to 27% using a two-sided binomial
test. For a more modest reduction from 40% to 30%
(odds ratio 0.64) the study would still have 80% power.
For the neonatal outcome, the Meis study found 7.2%
died, 14.6% had CLD and 5.2% had IVH on placebo,
compared to 4.6% death, 8.6% CLD and 1.3% IVH on
progesterone [4]. Our neonatal primary outcome is a
composite of these and also includes non-haemorrhagic
brain injuries. With n = 750 randomised, the
OPPTIMUM study would have 80% power at a 5% level
of significance to detect a difference in this composite
outcome of death, brain damage, or chronic lung disease
from 20 to 12%, using a binomial test.
The childhood developmental outcome at 2 years
will be assessed using the Bayley III Cognitive Scale
which correlates well with later IQ. With 750 rando-
mised, the study will have 93% power at a 5% level of
significance to detect a difference in means equivalent
to 0.25 of a standard deviations, using a two sample
two sided t-test. Based on previous work [29], we esti-
mate the standard deviation will be about 15 points,
enabling us to detect a difference of 4 points in the
Bayley Score. In clinical terms, a difference of 4 points
is small, thus the power of the study to detect larger,
more clinically significant differences, is high. We have
powered this outcome at over 90% to make some al-
lowance for a possible dilution of the power due to
incorporating the deaths (using a two stage statistical
model).
The revised sample size calculation below, based on blinded
data (as of April 2011) and inclusion of the "fFN"- group is
around 1250 participants
Obstetric outcome (delivery <34 weeks).
The table below gives the estimated power for three
combinations of sample size (all 1:2 fFN+/fFN- groups,
assuming 375:750 (total 1125), 400:800 (total 1200) and
425:850 (total 1275) assuming (fFN+, fFN-) event rates
(delivery < 34 weeks) of (40%, 10%), (45%, 13%), and
(45%, 15%). All calculations assume a relative treatment
effect of 32.5%.
The justification for these combinations is as follows:
1. The 40% untreated rate is as per the original
assumption. We have looked at the blinded
(aggregated) event rate for the first 67 women
randomised in OPPTIMUM (ignoring any possible
bias created by recording the early births before
later births in the most recently randomised). For
the fFN+ group, 29/67 (43%, 95% exact confidence
interval 31% to 56%) had delivered at <34 weeks.
The blinded event rate according to the assumed
40% untreated rate with a 27% treated rate (32.5%
relative reduction) would be 33.5%. Although the
numbers are relatively small, there appears to be a
higher event rate than anticipated, which would be
consistent with having selected a higher risk and
hence scarcer subset than we planned for). An
overall blinded rate of 43% could comprise an
untreated rate of 52% and a treated rate of 35%. We
assume conservatively that the baseline event rate in
the untreated fFN+ group is 45%.
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2. For the fFN- group women data on the first 24
women suggested that 8/24 (33%, exact 95%
confidence interval 16% to 55%) had delivered early.
As indicated above, this percentage is likely to be
inflated since we record the early deliveries before
observing the term deliveries. However, fortunately,
we also had followed up those who were not
randomised (by definition, all of whom had a
negative fFN test) into OPPTIMUM from the start.
Of the 398 followed, 32 have had a delivery
<34 weeks. We know that 57% of these 398 would
have been eligible for the trial (short
cervix < 25 mm), and the epidemiology indicates that
it is very unlikely to give birth <34 weeks with none
of the classic risk factors. So we conservatively
estimate that around 13% (i.e. around 29/225, exact
confidence interval 9% to 18%) of those recruited
into the fFN- group, based on OPPTIMUM data,
will have a delivery <34 weeks.
The conclusion is that it seems likely that if we recruit
at least 1125 (375:750) we will have almost 90% for the
primary obstetric outcome, assuming a slightly higher
rate in the fFN+ group (45% rather than 40%) and a
corresponding untreated event rate of 13% in the fFN-
women. If as we expect from the early returns the fFN-
event rate is >15%, we will be comfortably powered at
the original 95% for the obstetric outcome. Table 1
shows the various power scenarios.
The neonatal outcome (neonatal death, severe
chronic lung disease, intraventricular haemorrhage).
Data from the first cohort of women randomised (and
in particular those randomised in the low risk group)
into OPPTIMUM was even sparser for this outcome, as
it is determined by convention to up to 30 days after a
full term birth. For all those randomised with mature
data at the time of analysis, 11/68 have had the compos-
ite neonatal outcome (16%, exact 95% confidence inter-
val of 8% to 27%). Given that the rate of pre-term birth
is higher than anticipated, it seems reasonable to inflate
the assumed neonatal event rate from 20% to 25% (giv-
ing an blinded event rate of 20%, assuming a 40% rela-
tive reduction – and 20% is very consistent with the
observed 95% confidence interval of 8% to 27%). If we
then further assume a pro-rata event rate in line with
the rates of delivery <34 weeks on the obstetric outcome,
with the fFN- having roughly one-third the events of the
fFN+ i.e. 8% rather than 25%, then Table 2 below shows
the various power scenarios:
We conclude that by randomising at least 375 fFN+
and 750 fFN- women, assuming an untreated rate of
25% of the composite of neonatal death, severe chronic
lung disease, intraventricular haemorrhage in the fFN+,
and 8% in the fFN-, with an assumed 40% relative
treatment effect (as per original calculation) the original
power of the study for this neonatal outcome will be
preserved at >80% power.
The childhood development outcome (Bayley Score
at 2 years).
There are no data yet on this outcome within OPPTI-
MUM. In the original calculation we assumed that the
difference in mean Bayley score would be 4 units with a
common standard deviation of 15 units. It is more diffi-
cult to assess the power convincingly with a mixture of
fFN+ and fFN- women on a continuous outcome such
as the Bayley Score, since the power calculation requires
assumptions about not just the anticipated treatment ef-
fect but also the assumed variability via the standard de-
viation. If we assume the same 4 unit difference in the
fFN+ and a 4/3 unit difference in the fFN- group (con-
sistent with the pro-rata rate of delivery <34 weeks),
with the same 15 unit standard deviation, then the study
will have 71%, 73%, and 76% power if 1125, 1200, or
1275 are randomised (375:750, 400:800; and 425:850) as
per Tables 1 and 2 above. However, this is for an un-
adjusted analysis, and in practice we will adjust for fFN+
and fFN- group, and a limited number of other baseline
covariates strongly related to Bayley Score at 2 years
(e.g. gender) as specified in the statistical analysis plan,
and this will reduce the variability and hence increase
the power. For example, if the underlying variability in
the lower risk group is lower – say halved, at 7.5
units, consistent with a higher proportion having uni-
formly high Bayley Scores since they have no disability
– then the approximate power would be 93%, 94%,
and 95% respectively for 1125, 1200, or 1275
Table 1 Power scenarios for the neonatal outcome
fFN+ fFN- Subjects (fFN+/fFN-) [Total] Power
40% 10% 375/750 (1125) 81%
400/800 (1200) 83%
425/850 (1275) 85%
45% 13% 375/750 (1125) 88%
400/800 (1200) 90%
425/850 (1275) 92%
50% 15% 375/750 (1125) 93%
400/800 (1200) 94%
425/850 (1275) 95%
Table 2 Power scenarios for the obstetric outcome
fFN+ fFN- Subjects (fFN+/ fFN-) [Total] Power
25% 8% 375/750 (1125) 81%
400/800 (1200) 83%
425/850 (1275) 86%
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randomised in total. In practice the reduction in vari-
ability by adjusting for both this design variate (fFN+
and fFN- ) and additional baseline covariates may be
considerably greater, so we are confident that the ori-
ginal power on the childhood development outcome
will be protected at or above the original 90% level by
randomising at least 1125 subjects (375:750).
Endnotes
ahttp://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm242234.htm
bhttp://www.cbsnews.com/8301-505245_162-57363066/
fda-panel-votes-down-preterm-birth-gel/
chttp://www.rcog.org.uk/womens-health/guidelines/
use-progesterone-prevent-preterm-delivery
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